 Nephrotoxicity allopurinol experimental hypertension Hyperuricemia present pediatric adult patients essential hypertension metabolic abnormality additional risk factor development cardiovascular disease following studies hyperuricemia prevalent hypertensive rat SHR allopurinol treatment beneficial effect development hypertension strain capacity serum uric acid concentration antioxidant agent SHR Wistar-Kyoto WKY rats groups tap water provided water allopurinol mg/l approximate daily equal mg/kg body wt treatment weeks serum uric acid levels similar untreated SHR WKY rats versus mg/dl control WKY rat strain allopurinol therapy affect weight gain hematocrit increase mortality moderate decrement kidney function creatinine clearance allopurinol-treated group versus control group body wt conjunction mild-to-moderate tubulointerstitial inflammation allopurinol-treated group versus control group